Filing · LD-2 quarterly report
Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 19, 2026
Expenses
$260,000
What this organization spent lobbying with its own staff.
Reported using the LDA's own definitions (method A): the three
LDA methods count different costs, so an expenses figure is
not comparable across filers that used different ones.
Client based in
District of Columbia
Government bodies contacted
2
Lobbying activity
3
Issues related to fertility treatment, oncology and coverage, including: H.R. 8119, the HOPE with Fertility Services Act; H.R. 1670 and S. 797, the Family Building FEHB Fairness Act; H.R. 220, the Veterans Infertility Treatment Act; H.R. 7841, Warrior Infertility Act; H.R. 6797, the Bipartisan IVF for Military Families Act; and H.R. 4299, the Protecting Patient Access to Cancer and Complex Therapies Act.
Issues related to establishing a tax credit for fertility treatments, including: H.R. 1878, the IVF Access and Affordability Act; and H.R. 4639, the Infertility Treatment Affordability Act.
Issues related to the treatment of pharmaceutical ingredients in trade agreements.